Identification of chicken-derived antibodies targeting the Candida albicans Als3 protein

Chi-Hsin Lee1,2,3, Chao-Jung Wu1,2, Fang-Yi Yen1

  • 1School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, No. 301, Yuantong Rd., Zhonghe Dist., New Taipei City, 235, Taiwan.

Insights

Researchers developed chicken-derived single-chain variable fragment (scFv) antibodies targeting Candida albicans Als3 protein. These antibodies show high affinity and specificity, offering potential for new immunotherapies against C. albicans infections.

Area of Science:

  • Immunology and Microbiology
  • Biotechnology and Antibody Engineering

Background:

  • Candida albicans is a significant opportunistic pathogen causing candidemia, with increasing azole resistance posing a clinical challenge.
  • Agglutinin-like sequence 3 (Als3) is a crucial cell surface protein in C. albicans, vital for adherence and biofilm formation during infection.
  • Monoclonal antibody therapies present a promising avenue for developing novel treatments against C. albicans infections.

Purpose of the Study:

  • To generate and characterize high-affinity single-chain variable fragment (scFv) antibodies targeting the Als3 protein of Candida albicans.
  • To evaluate the specificity and binding capabilities of these novel scFv antibodies for potential immunotherapeutic applications.

Main Methods:

  • Recombinant Als3 protein was used to immunize chickens, producing Als3-specific immunoglobulin Y (IgY) antibodies.
  • Two single-chain variable fragment (scFv) antibody libraries were constructed using phage display technology.
  • Phage-based ELISA and bio-panning were employed to identify and validate scFv antibodies with high binding affinity to Als3.

Main Results:

  • Three scFv antibodies were successfully identified, demonstrating strong binding activity to Als3 via ELISA and western blot.
  • The selected scFv antibodies exhibited high binding affinities, in the range of approximately 10⁻⁸ M.
  • These scFv antibodies specifically recognized endogenous Als3 protein in C. albicans, confirmed by western blot and cell-based ELISA.

Conclusions:

  • This study successfully generated high-affinity, specific scFv antibodies targeting the C. albicans Als3 protein.
  • The characterized scFv antibodies hold significant potential as immunotherapeutic agents for treating C. albicans infections.
  • Als3 serves as a critical biomarker and therapeutic target for developing novel anti-Candida strategies.